Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2025-02-17 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations of the company Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It explains the situation, confirms no undisclosed material information, and reminds investors of market risks. It does not contain financial statements, detailed financial data, or management analysis. It is a regulatory disclosure about stock trading behavior and compliance with stock exchange rules, typical of a Regulatory Filing (RNS). The document length is short (1447 characters), and it is not a report or presentation but a formal announcement about stock price abnormality and related investigation results.
2025-02-17 Chinese
关于股份回购结果暨股份变动的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement about the completion of a share repurchase program by Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes specifics on the number of shares repurchased, prices, dates, regulatory compliance, and future plans for the repurchased shares. The text references multiple prior announcements about the repurchase plan and progress updates, and it confirms that the repurchase plan has been fully implemented. The document does not contain financial statements or earnings data but focuses on the company's own shares transactions. This matches the definition of a 'Transaction in Own Shares' filing, which reports on the company's buyback or sale of its own shares. The document length is about 4159 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the correct classification is POS (Transaction in Own Shares).
2025-01-23 Chinese
2024年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2024年度业绩预告' which translates to '2024 Annual Performance Forecast'. It provides preliminary profit estimates for the full fiscal year 2024, including net profit attributable to shareholders and net profit excluding non-recurring items, with comparisons to the prior year. It explicitly states that the data is preliminary, unaudited, and based on internal estimates, with final audited results to be disclosed in the official 2024 annual report. The document also mentions communication with the audit firm but no audit has been completed yet. The length is short (1141 characters), and it is a forward-looking earnings forecast rather than a full financial report or audited results. This fits the definition of an Earnings Release (ER), which is an initial announcement of periodic financial results or forecasts with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is not a Report Publication Announcement (RPA) because it contains substantive preliminary financial data, not just a notice of report availability. Therefore, the correct classification is Earnings Release (ER). FY 2024
2025-01-20 Chinese
关于董事会和监事会换届延期公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the postponement of the board of directors and supervisory board re-election. It discusses the extension of the current board and management terms to ensure continuity and stability. There is no financial data, no mention of annual or interim reports, no audit information, and no other report types. The content clearly relates to changes or updates about the company's board and senior management. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2025-01-17 Chinese
监事会关于公司2024年限制性股票激励计划首次授予激励对象名单（截至授予日）的核查意见
Capital/Financing Update Classification · 90% confidence The document is a supervisory board opinion on the verification of the initial grant list of a 2024 restricted stock incentive plan for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It discusses compliance with relevant laws, regulations, and company articles regarding the eligibility of incentive recipients. The document is a formal verification and approval statement related to a stock incentive plan, not a full report, financial statement, or announcement of voting results. It does not contain financial data or detailed financial performance information. It is not a regulatory filing or certification letter but a supervisory board opinion on a capital incentive plan. This fits best under Capital/Financing Update (CAP) as it relates to stock incentive plan grants and capital-related employee incentives.
2025-01-03 Chinese
深圳价值在线咨询顾问有限公司关于上海泓博智源医药股份有限公司2024年限制性股票激励计划调整及首次授予事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding the 2024 Restricted Stock Incentive Plan adjustment and initial grant for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It is issued by Shenzhen Value Online Consulting Co., Ltd. The content includes detailed explanations of the incentive plan, approval procedures, grant conditions, and the advisor's opinions. It is a standalone advisory report related to a stock incentive plan, not a general annual or quarterly financial report, earnings release, or regulatory filing. It does not contain financial statements or earnings data but focuses on the stock incentive plan and related approvals. This fits the category of an Audit Report / Information (AR) as it is an independent financial advisor's report on a specific corporate action related to stock incentives, including compliance and approval verification, rather than a full annual report or other categories. FY 2024
2025-01-03 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.